Changes in Insulin-Like Growth Factor-I and -II Associated with Fat but not Lean Mass in Early Old Age

David Bann[1], Jeff M.P. Holly[2], Hany Lashen[3], Rebecca Hardy[1], Judith Adams[4], Diana Kuh[1], Ken K. Ong[5*], and Yoav Ben-Shlomo[6*]

Objective: To test the hypothesis that insulin-like growth factors-I and II (IGF-I and II) decline during late midlife and that greater declines are related to higher fat mass and lower lean mass.

Methods: A total of 1,542 men and women in a British birth cohort study had IGF-I and II measured by immunoassay of blood samples at age 53 and/or 60-64 years. Fat mass, android:gynoid fat ratio, and appendicular lean mass were measured at 60-64 years using dual-energy X-ray absorptiometry (DXA). Associations between changes in IGF-I or II and body composition outcomes were examined using conditional change linear regression models.

Results: Mean IGF-I and IGF-II concentrations were lower at 60-64 than at 53 years, by 12.8% for IGF-I and by 12.5% for IGF-II. Larger declines in either IGF-I or II were associated with higher fat mass at 60-64 years. Although higher IGF-I at 53 years was associated with higher lean mass, there was little evidence linking changes in IGF-I or II to lean mass.

Conclusions: The findings suggest that IGF-I and II concentrations decline with age, and greater declines are associated with higher fat mass levels. These results provide some evidence for the suggested roles of IGF-I and II in regulating fat mass but not lean mass in older age.

Introduction

Insulin-like growth factors-I and II (IGF-I and II) are known to regulate growth in early life and are postulated to have multifaceted roles in adult life (1,2). Evidence from multiple sources suggests that these roles could include the regulation of body composition (fat and lean (muscle) mass). This is important to understand given the high worldwide prevalence of obesity and its well-documented adverse consequences for health and physical functioning (3,4), and the likely independent adverse effects of low lean mass in old age (5).

Animal studies have suggested that IGF-I may facilitate the maintenance of muscle satellite cells, which aid exercise-induced muscle hypertrophy (6,7). Small experimental studies in humans have shown that supplementation of growth hormone (the up-stream physiological regulator of IGF-I) leads to losses in fat and gains in lean mass (8), and Laron syndrome (genetic insensitivity to growth hormone) is characterized by high fat mass levels which are reversed

by IGF-I therapy (9). Experimental studies have also shown that obese people have blunted IGF-I generation in response to growth hormone stimulation, suggesting bi-directionality in the association between IGF-I and fat mass (8).

Although IGF-II concentrations in adults are three- to fivefold higher than IGF-I concentrations (10), its roles are less well understood (11), particularly because IGF-II is not expressed postnatally in mouse models unlike in humans. Genetic and epigenetic studies have suggested that IGF-II may regulate fat and lean mass: IGF-II genetic variants have been associated with body weight (12) and lean mass (13), and epigenetic differences in IGF-II have been associated with skinfold thickness (14).

Observational studies can contribute to understanding how IGF-I and II concentrations change with age, and how these changes impact on body composition. Limited evidence from cross-

[1] MRC Unit for Lifelong Health and Ageing, University College London, London, UK [2] IGFs and Metabolic Endocrinology, School of Clinical Sciences, Bristol University, Bristol, UK [3] Department of Human Metabolism, The University of Sheffield, Sheffield, UK [4] Department of Radiology, Central Manchester University Hospital NHS Foundation Trust, Manchester Academic Health Science Centre, Oxford Road, Manchester, UK [5] MRC Epidemiology Unit, University of Cambridge, Cambridge, UK. Correspondence: David Bann (david.bann@ucl.ac.uk) [6] School of Social and Community Medicine, Bristol University, Bristol, UK.

sectional studies shows that IGF-I concentrations are lower in old age (15-18), suggesting that the decline in IGF-I may be implicated in age-related gains in fat and losses in lean mass (19). IGF-I has been cross-sectionally inversely associated with body mass index (BMI) or body weight (20), with some studies reporting that those with lowest or highest BMI have lower IGF-I (21,22). However, such findings do not elucidate whether IGF-I is associated with fat and/or lean mass. Cross-sectional studies of body composition measures have yielded equivocal findings with IGF-I, and few have examined associations with IGF-II (23), leading to uncertainty in the roles of IGF-I and II in regulating body composition.

The objectives of this study were to examine the relevance of age-related changes in circulating IGF-I and II concentrations during late midlife to fat and lean body mass in a British birth cohort study. The strengths of this study are the repeat measures of IGF-I and II, 7-11 years apart, a large sample of both sexes, and measures of body composition obtained in early old age using dual-energy X-ray absorptiometry (DXA). We hypothesized that larger decline in IGF-I and II would be associated with higher fat and lower lean mass.

Methods

Study sample

The MRC National Survey of Health and Development (NSHD) is a socially stratified sample of 5,362 singleton births that took place in 1 week of March 1946 in mainland Britain, with regular follow-up across life. Between 2006 and 2010 (at 60-64 years), 2,856 eligible study members (those known to be alive and with a known address in England, Scotland, or Wales) were invited for an assessment at one of six clinical research facilities (CRFs) or to be visited by a research nurse at home. Invitations were not sent to those who had died ($n = 778$), who were living abroad ($n = 570$), had previously withdrawn from the study ($n = 594$) or who had been lost to follow-up ($n = 564$). Of those invited, 2,229 (78%) were assessed: 1,690 (59.2%) attended a CRF and the remaining 539 were seen at home (24).

Body composition measurement

During the visits to the CRF, measures of body composition were obtained in the supine position using a QDR 4500 Discovery DXA scanner (Hologic, Bedford, MA) with APEX 3.1 analysis software. From these scans, measures of fat (whole body, abdominal (android) and hips (gynoid)) and appendicular (limb) lean mass were obtained and converted into kilograms. The ratio of android:gynoid fat mass was derived (higher values indicating greater fat distribution in the abdomen than hips) and multiplied by 100. Lean mass was defined as body mass excluding fat mass and bone mineral content (BMC), and in all measures data from the head were excluded due to the high proportion of BMC known to affect the accuracy of soft-tissue measures. Measures selected for analysis were: whole body fat mass (kg), android:gynoid ratio (multiplied by 100), and appendicular lean mass (kg). Data on these outcomes were available for 1,558 participants, with missing data in 132 participants largely due to the presence of high-density artefacts (e.g., joint replacements). The study received multicenter research ethics committee approval, and informed consent was given by participants.

Measurement of IGFs

At 53 years, non-fasting venous blood samples were taken in tubes containing ethylenediaminetetraacetic acid (EDTA) during home visits by research nurses. These were posted overnight to a laboratory where plasma was extracted and frozen at $-80°C$. At 60-64 years, overnight fasting venous blood samples were obtained in tubes containing liquid citrate. These were then taken immediately to a laboratory in each CRF (clinic visit) or posted overnight to a CRF (home visit) and plasma extracted before being frozen at $-80°C$. IGF-1, IGF-II, and IGFBP-3 were obtained by radioimmunoassay using standardized protocols in the same laboratory; in all except 200 pilot samples, assays were conducted in duplicate and mean values used in analyses. Intra-assay coefficients of variation were 3.4% for IGF-I, 2.8% for IGF-II, and 3.9% for IGFBP-3. Assays were repeated where intra-assay coefficients of variation exceeded 15%. Inter-assay coefficients of variation were 13.7% (IGF-I), 7.4% (IGF-II), and 11.7% (IGFBP-3); to minimize inter-assay variability, in most instances the same laboratory technician assayed each analyte.

Analytical strategy

As taller individuals tend to have more fat and lean mass, height-adjusted indices were created by dividing fat and appendicular lean mass (kg) by height(m)^X, where X was calculated so that the resulting index was not correlated with height ($X = 1.2$ for fat and 2 for lean mass) (25).

First, the associations of IGF-I and IGF-II at 53 and 60-64 years with fat and lean mass at 60-64 years were examined using linear regression. To aid the interpretation of model coefficients, each IGF measure was converted into sex-specific z-scores, and outcomes were log transformed and multiplied by 100; regression coefficients therefore show the mean percentage difference in outcome per 1 standard deviation increase in IGF. Findings did not differ when IGF measures were modeled as either z-scores or as absolute values. Second, associations between change in IGF-I and II and fat and lean mass were examined using conditional change models—calculated change in IGF was included in models that also included the baseline IGF concentration at 53 years. Change scores were converted to sex-specific z-scores to aid interpretation of model coefficients. Given previous evidence for sex differences in associations (26), sex interaction terms were tested—where significant interactions were found ($P < 0.05$), models were conducted separately in each sex; otherwise models were adjusted for sex.

Associations with lean mass could be confounded by fat mass, as changes in fat mass typically lead to adaptive changes in lean mass (27). As such, models using lean mass as an outcome were additionally adjusted for fat mass. The change models were also additionally adjusted for further potential confounders at age 53 identified a-priori: household occupational class, smoking status (categorized as non-smoker or light (1-10), moderate (11-20), or heavy smoker (>20 cigarettes per day)) and menopausal status (categorized as pre-, peri-, or post-menopausal, hysterectomy with or without hormone replacement therapy, other hormone replacement therapy user, or other reason for menstrual period cessation) (28). Complete case analyses were performed to examine IGF and body composition associations: 594 men and 644 women had complete body composition and IGF data at both ages; of these, 588 men and 623 women also had complete data for all potential confounders.

TABLE 1 Summary of body composition and IGF concentrations by sex

	Men, mean (SD or IQR)	Women, mean (SD or IQR)	P^a
Body composition at 60-64 y	$N = 746$	$N = 812$	
Fat mass index (kg m^{-2})	12.02 (3.63)	16.20 (4.97)	<0.001
Android fat mass (kg)	2.47 (0.96)	2.34 (0.98)	0.02
Gynoid fat mass (kg)	3.73 (1.00)	5.11 (1.41)	<0.001
Android:gynoid ratio	65.16 (15.50)	44.93 (12.04)	<0.001
Appendicular lean mass index (kg m^{-2})	8.02 (0.95)	6.19 (0.87)	<0.001
IGF concentration, age	$N = 744$	$N = 798$	
IGF-I (ng ml^{-1}), 53 y	211.2 (66.3)	194.6 (67.9)	<0.001
IGF-I (ng ml^{-1}), 60-64y	185.7 (59.9)	168.2 (58.6)	<0.001
Δ IGF-I (ng ml^{-1})	−25.5 (−60, 14)	−26.4 (−67, −24)	0.80
IGF-II (ng ml^{-1}), 53 y	747.7 (254.2)	796.6 (247.6)	<0.001
IGF-II (ng ml^{-1}), 60-64 y	647.0 (308.0)	703.0 (291.5)	<0.001
Δ IGF-II (ng ml^{-1})	−100.6 (−321, 99)	−93.5 (−358, 115)	0.70
IGFBP-3 (ng ml^{-1}), 53 y	4781.7 (1083.2)	4835.9 (1122.5)	0.30
IGFBP-3 (ng ml^{-1}), 60-64 y	3219.5 (832.4)	3457.7 (831.5)	<0.001
Δ IGFBP-3 (ng ml^{-1})	−1562.2 (−2244, −881)	−1378.1 (−2142, −592)	<0.001
IGF-I:IGFBP-3, 53 y	4.6 (1.7)	4.2 (1.9)	<0.001
IGF-I:IGFBP-3, 60-64 y	6.0 (2.5)	5.0 (1.5)	<0.001
Δ IGF-I:IGFBP-3	1.4 (0.17, 2.6)	0.8 (−0.35, 1.9)	<0.001

[a]Comparison between sexes using *t* tests; IGF-I/IGFBP-3 ratio was multiplied by 100; analyses restricted to participants with valid data for all body composition outcomes or all hormone measures at both ages.

Additional and sensitivity analyses

To examine the possibility of reverse or bi-directionality, change models with fat mass were repeated with additional adjustment for BMI at 53 (as DXA measures were not available at 53), and analyses were conducted in which BMI (or change in BMI) was the exposure, and IGF-I or II the outcome. As IGF-I and physical activity may influence muscle mass synergistically (7), we also examined whether physical activity modified the association between IGF-I and lean mass by including an interaction term with leisure time physical activity at both 53 and 60-64 years (categorized as no participation, 1-4 episodes, and ≥5 episodes in the previous 4 weeks). To examine the extent to which associations between IGF and body composition were driven by height, we also conducted analyses without adjustment for height. To examine whether associations between IGFs and body composition outcomes were non-linear, we examined plots of the data and compared linear models with models additionally including quadratic terms for IGFs. We also examined whether associations between changes in IGFs and body composition were non-linear, by repeating analyses using change score variables converted into quartiles. These categorical models were then compared with linear models using likelihood ratio tests.

Results
Descriptive analyses

At both 53 and 60-64 years, men had higher IGF-I but lower IGF-II concentrations than women (Table 1). In both sexes, mean IGF-I and II concentrations were lower at 60-64 than 53 years—by 12.8%

for IGF-I and 12.5% for IGF-II; larger declines were seen in IGFBP3 and therefore the mean IGF-I:IGFBP3 ratio was higher at 60-64 years. Most, but not all, participants showed a decline in IGF-I (66%) and IGF-II (65%) concentrations (Supporting Information Figure 1). Women had greater whole body fat and less lean mass than men, and a lower android:gynoid ratio.

IGF-I showed moderately positive correlations with IGF-II and IGFBP-3 at both 53 and 60-64 years (Supporting Information Table 1).

Associations between IGFs and fat mass

IGF-I at 53 (in women) and 60-64 years (both sexes) was inversely associated with fat mass at 60-64 (Table 2). Conversely, IGF-II at 53 years was positively associated with fat mass, while IGF-II at 60-64 years was inversely associated with fat mass. Associations between IGF-I or II with BMI and android:gynoid ratio at 60-64 years was generally similar to those with fat mass index (Supporting Information Table 2).

Greater decline in IGF-I between 53 to 60-64 years was weakly and non-significantly associated with higher fat mass, and higher android:gynoid ratio at 60-64 years (Table 2). Greater decline in IGF-II was associated with higher fat mass, but not android: gynoid ratio. These associations were similar albeit partly attenuated when additional adjustment was made for potential confounders (Table 2). Associations of IGFBP-3 and IGF-I: IGFBP-3 with these outcomes are shown in Supporting Information Table 3.

TABLE 2 Mean percentage differences in fat mass and android:gynoid ratio (95% CI) at age 60-64 years per 1 standard deviation increase in IGF-I and IGF-II at 53 and 60-64 years

			Fat mass index			Android:gynoid fat mass ratio		
		_N_	β (95% CI)	_P_	_P_ (sex interaction)	β (95% CI)	_P_	_P_ (sex interaction)
IGF-I at 53y	Men	627	0.38 (−2.04, 2.79)	0.76	<0.01	−0.30 (−1.74, 1.13)	0.68	0.16
	Women	704	−4.06 (−6.26, −1.85)	<0.001				
IGF-I at 60-64 y		1,434	−2.12 (−3.71, −0.52)	<0.01	0.94	−0.73 (−2.11, 0.66)	0.30	0.15
Δ IGF-I		1,211	−1.86 (−4.02, 0.30)	0.09	0.61	−1.33 (−3.23, 0.57)	0.17	0.24
Δ IGF-I, adjusted*		1,211	−1.56 (−3.71, 0.59)	0.16	0.51	−0.96 (−2.86, 0.94)	0.32	0.19
IGF-II at 53y		1,331	3.24 (1.61, 4.86)	<0.001	0.26	2.71 (1.28, 4.14)	<0.001	0.30
IGF-II at 60-64 y		1,434	−1.55 (−3.15, 0.05)	0.06	0.09	0.76 (−0.63, 2.14)	0.28	0.55
Δ IGF-II		1,211	−2.01 (−4.05, 0.03)	0.05	0.10	0.27 (−1.53, 2.06)	0.77	0.26
Δ IGF-II, adjusted[a]		1,211	−1.94 (−3.96, 0.08)	0.06	0.11	0.26 (−1.53, 2.04)	0.78	0.27

Note: Sex-specific findings shown where _P_ (sex interaction)<0.05; otherwise, models are adjusted for sex. Δ change between 53 and 60-64 years—analyses adjusted for hormone concentration at 53 years.
[a]Adjusted for highest household occupational class, smoking, and menopausal status at age 53 years.

Associations between IGFs and lean mass

After adjustment for fat mass, IGF-I at 53 was positively associated with appendicular lean mass at 60-64 years, while associations between IGF-I at 60-64 years and lean mass were weak and not significant (Table 3). After adjustment for fat mass, IGF-II was not associated with lean mass in either sex, and nor were changes in IGF-I or II.

Additional and sensitivity analyses

Associations between declines in IGF-I and II and fat mass were similar after additional adjustment for BMI at 53 years (_P_ = 0.04 for IGF-I and _P_ = 0.13 for IGF-II; Supporting Information Table 4). Greater gain in BMI from 53 to 60-64 years (modeled as the exposure) was weakly associated with lower IGF-I at 60-64 years (modeled as the outcome), but not with IGF-II at 60-64 years (Supporting Information Table 5).

There was no evidence for effect modification by physical activity in the association between IGF-I and lean mass (_P_ values for interaction term>0.4 at both 53 and 60-64 years). For all outcomes, conclusions did not differ when not adjusting for adult height. There was no substantive evidence for deviation from linearity with IGF at

TABLE 3 Mean percentage differences in appendicular lean mass (95% CI) at age 60-64 years per 1 standard deviation increase in IGF-I and IGF-II at 53 and 60-64 years

			Appendicular lean mass index, unadjusted			Appendicular lean mass index, adjusted for fat mass index		
		_N_	β (95% CI)	_P_	_P_ (sex interaction)	β (95% CI)	_P_	_P_ (sex interaction)
IGF-I at 53 y	Men	627	0.97 (0.05, 1.89)	0.04	<0.01	0.65 (0.10, 1.21)	0.02	0.19
	Women	704	−1.02 (−2.03, −0.01)	0.05				
IGF-I at 60-64y		1,434	−0.39 (−1.05, 0.28)	0.25	0.86	0.26 (−0.28, 0.80)	0.34	0.87
Δ IGF-I		1,211	−0.75 (−1.66, 0.16)	0.11	0.62	−0.25 (−0.98, 0.49)	0.51	0.65
Δ IGF-I, adjusted[a]		1,211	−0.69 (−1.60, 0.22)	0.14	0.70	−0.28 (−1.01, 0.46)	0.46	0.83
IGF-II at 53 y		1,331	0.95 (0.26, 1.63)	<0.01	0.33	0.23 (−0.33, 0.79)	0.41	0.69
IGF-II at 60-64 y		1,434	−0.34 (−1.01, 0.32)	0.31	0.84	0.10 (−0.44, 0.64)	0.72	0.33
Δ IGF-II		1,211	−0.43 (−1.29, 0.43)	0.33	0.56	0.11 (−0.58, 0.81)	0.75	0.53
Δ IGF-II, adjusted[a]		1,211	−0.33 (−1.19, 0.53)	0.45	0.67	0.19 (−0.50, 0.89)	0.59	0.42

Note: Sex-specific findings shown where _P_ (sex interaction) < 0.05; otherwise, models are adjusted for sex. Δ change between 53 and 60-64 years—analyses adjusted for hormone concentration at 53 years.
[a]Adjusted for highest household occupational class, smoking, and menopausal status at age 53 years.

each age, nor with change in IGF-I or II (*P* values from likelihood ratio tests >0.35 in all cases).

Discussion

Longitudinal data from a large British birth cohort study showed evidence for declines in both IGF-I and II concentrations during late midlife (53 to 60-64 years), which were associated with higher fat mass at 60-64 years. While IGF-I at 53 years was positively associated with lean mass at 60-64 years, there was little evidence that changes in IGF-I and II, per se, were associated with lean mass in either sex.

Our findings add substantially to previous cross-sectional evidence for lower IGF-I concentrations in older versus younger adults (15-18), and one small longitudinal study which reported a decline in IGF-I during mid-late life among participants enrolled in a colonoscopy study ($N = 143$) (29). The results also add to previous cross-sectional studies conducted on smaller samples which reported equivocal findings on the relationship between IGF-I and body composition. For example, in a cross-sectional study of Dutch older adults, IGF-I was inversely associated with BMI, and weakly inversely associated with fat and lean mass in men, but not women (26). In other cross-sectional studies of adults, IGF-I was inversely (30), positively (31), or not associated with lean mass (32,33); and inversely (32), or not associated with fat mass (30,31,33). Previous studies have also found evidence that the IGF-I and BMI cross-sectional association is non-linear, with those with highest or lowest BMI having lower IGF-I (21,22). However, there was little evidence for this in our models using either fat mass or BMI as the outcome (Supporting Information Figures 2 and 3) with mean IGF-I levels declining with increasing quintiles of body mass or fat mass index.

Taken together, these results provide some evidence to support the roles of IGF-I and II in the regulation of fat mass. The weak magnitude of associations (and non-significant *P* values found in some cases) may be explained by the contribution of other influences on fat mass which we were unable to control for, and by imprecision in the extent to which a single measure of circulating IGF reflects long-term concentrations (e.g., due to day-do-day variation) and bioactivity. The presence of feedback loops may also weaken observed associations. For example, while increases in IGF-I may reduce fat mass levels, higher IGF-I would also down-regulate growth hormone secretion, which in turn would result in lower IGF-I. Associations between IGF-I and fat mass could also be explained in part by reverse causation or bi-directionality, as obese subjects are known to have relative growth hormone insensitivity compared with nonobese subjects (8). Although associations between change in IGF-I and fat mass were not substantively attenuated after adjustment for BMI at 53 year, greater gains in BMI were (weakly) associated with lower IGF-I. Finally, IGF-I could simply be a surrogate marker for the direct actions of growth hormone on mature adipocytes (8).

Lack of association, or weak association, between changes in total serum IGF concentrations and lean mass could suggest that IGF-I or II are not important regulators of adult lean mass. This is contrary to reported findings from some studies which reported higher adult protein intake, a likely determinant of muscle mass, associated with higher IGF-I concentrations (34). However, our findings do not preclude the importance of IGF-I and II in regulating muscle growth in early life, nor local IGF actions on adult lean mass—some experimental studies have shown that exercise increases local (muscle) IGF-I but not total serum IGF-I concentrations (35).

Unlike total IGF-I concentrations, mean IGF-I:IGFBP-3 ratio increased between 53 to 60-64 years due to the relatively larger decline in IGFBP-3. IGFBP-3 is one of six binding proteins that carry IGF-I in circulation. If IGFBP-3 acts as an inert carrier protein, then the IGF-I:IGFBP-3 ratio could better indicate biologically available IGF-I than total IGF-I concentration. However, evidence for direct biological actions of IGFBP-3 suggests otherwise—IGFBP-3 and other IGF binding proteins have their own cellular actions which include enhancing IGF activity (36). As such, associations between IGF-I:IGFBP-3 ratio and outcomes should be interpreted with caution. However, directly measured "free" and/or bioactive IGF-I or II may decline with age, and its decline may relate more closely to body composition outcomes than total measures. This warrants investigation in future studies although at present there are no universally accepted standardized methods for measuring "free" or bioactive concentrations of IGFs and the interpretation of these measurements is still subject to discussion.

It is unclear what up-stream factors cause the observed age-related declines in IGF-I and II. IGF-I has been hypothesized to be a biomarker which mediates the roles of physical activity (and other factors) on body composition and health outcomes (37). However, it remains unclear if this is the case. While studies have consistently found greater milk consumption in early life is associated with lower IGF-I concentration in adulthood (38), studies examining the adulthood determinants of IGF have yielded equivocal findings [e.g., in relation to reported energy intake and physical activity level (20)]. These determinants are being investigated in the NSHD and warrant investigation in other cohorts.

Strengths of this study include the accurate measures of fat and lean mass in both sexes, and repeat measures of both IGF-I and II. The single DXA measures obtained at 60-64 years however precluded the analysis of how changes in IGF relate to change in fat and lean mass. Intra-assay coefficients of variation were low, which limited measurement error; while inter-assay coefficient variations were larger, the ranking of participant IGF values was unlikely to be substantially affected as assay results were calibrated using control samples.

Limitations of study include loss to follow-up, which despite the large sample size reduced statistical power and may have introduced bias (if the exposure-outcome association differed in the sample lost to follow-up). Methodological differences in blood sample collection at 53 and 60-64 years could have affected the results obtained—the longer storage time of samples collected at 53 years could have resulted in IGF degradation, which would attenuate the declines in IGF-I and II observed with age. Conversely, the liquid citrate used at 60-64 years may have reduced IGF concentrations. Blood samples at 53 years were obtained during home visits, which likely resulted in a longer time to freezing compared with the 60-64 year samples. However, a methodological study suggested that time to freezing did not substantially affect IGF-I concentrations (39), and IGF-I and II concentrations at 53 years did not differ by time of day at sampling (morning, afternoon, or evening; $P > 0.3$ in all cases). More than two time points

of measurement would provide more informative data on the trajectories of change in IGF concentrations with age.

Findings from the present study add substantially to our understanding of the age-related changes in IGF-I and II, and their consequences for body composition. However, the implications of these findings are not straightforward. Lowering fat mass levels by pharmacological supplementation of IGF (or growth hormone) is likely to be unwarranted given expected increases in cancer risk (40). Rather, behavioral or early life interventions acting on the upstream determinants of IGF-I and II may potentially lessen their decline with age in later mid-life, and in turn could limit the accumulation of fat mass during this period of ageing.

Conclusion

Using longitudinal data from a British birth cohort study, evidence was found for declines in IGF-I and II concentrations from 53 to 60-64 years, and greater declines were weakly associated with higher fat mass at 60-64 years. There was little evidence that changes in IGF-I and II were associated with lean mass. O

Acknowledgments

References

1. Junnila RK, List EO, Berryman DE, Murrey JW, Kopchick JJ. The GH/IGF-1 axis in ageing and longevity. *Nat Rev Endocrinol* 2013;9:366-376.
2. Holly JMP, Perks CM. Insulin-like growth factor physiology: what we have learned from human studies. *Endocrinol Metab Clin North Am* 2012;41:249-263.
3. Flegal KM, Kit BK, Orpana H, Graubard BI. Association of all-cause mortality with overweight and obesity using standard body mass index categories: a systematic review and meta-analysis. *JAMA* 2013;309:71-82.
4. Rejeski WJ, Marsh AP, Chmelo E, Rejeski JJ. Obesity, intentional weight loss and physical disability in older adults. *Obes Rev* 2010;11:671-685.
5. Wolfe RR: The underappreciated role of muscle in health and disease. *Am J Clin Nutr* 2006;84:475-482.
6. Ye F, Mathur S, Liu M, et al. Overexpression of insulin-like growth factor-1 attenuates skeletal muscle damage and accelerates muscle regeneration and functional recovery after disuse. *Exp Physiol* 2013;98:1038-1052.
7. Adams GR. Role of insulin-like growth factor-I in the regulation of skeletal muscle adaptation to increased loading. *Exerc Sport Sci Rev* 1998;26:31-60.
8. Berryman DE, Glad CAM, List EO, Johannsson G. The GH/IGF-1 axis in obesity: pathophysiology and therapeutic considerations. *Nat Rev Endocrinol* 2013;9:346–356.
9. Klinger B, Laron Z. Three year IGF-I treatment of children with Laron syndrome. *J Pediatr Endocrinol Metab* 1995;8:149-158.
10. Birnie K, Ben-Shlomo Y, Holly JMP, et al. Associations of insulin and insulin-like growth factors with physical performance in old age in the Boyd Orr and Caerphilly studies. *Plos One* 2012;7:e30096.
11. Livingstone C, Borai A. Insulin-like growth factor-II: its role in metabolic and endocrine disease. *Clin Endocrinol (Oxf)* 2014;80:773-781.
12. Rodriguez S, Gaunt TR, Dennison E, et al. Replication of IGF2-INS-TH[ast]5 haplotype effect on obesity in older men and study of related phenotypes. *Eur J Hum Genet* 2005;14:109-116.
13. Schrager MA, Roth SM, Ferrell RE, et al. Insulin-like growth factor-2 genotype, fat-free mass, and muscle performance across the adult life span. *J Appl Physiol* 2004;97:2176-2183.
14. Huang RC, Galati J, Burrows S, et al. DNA methylation of the IGF2/H19 imprinting control region and adiposity distribution in young adults. *Clin Epigenet* 2012;4:1-11.
15. O'Connor KG, Tobin JD, Harman SM, et al. Serum levels of insulin-like growth factor-I are related to age and not to body composition in healthy women and men. *J Gerontol A Biol Sci Med Sci* 1998;53:M176-M182.
16. Bidlingmaier M, Friedrich N, Emeny RT, et al. Reference intervals for insulin-like growth factor-1 (IGF-I) from birth to senescence: results from a multicenter study using a new automated chemiluminescence IGF-I immunoassay conforming to recent international recommendations. *J Clin Endocrinol Metab* 2014;99:1712-1721.
17. Vestergaard PFL, Hansen M, Frystyk J, et al. Serum levels of bioactive IGF1 and physiological markers of ageing in healthy adults. *Eur J Endocrinol* 2014;170:229-236.
18. Seck T, Scheppach B, Scharla S, et al. Concentration of insulin-like growth factor (IGF)-I and -II in iliac crest bone matrix from pre- and postmenopausal women: relationship to age, menopause, bone turnover, bone volume, and circulating IGFs. *J Clin Endocrinol Metab* 1998;83:2331-2337.
19. Kuk JL, Saunders TJ, Davidson LE, Ross R. Age-related changes in total and regional fat distribution. *Ageing Res Rev* 2009;8:339-348.
20. Parekh N, Roberts CB, Vadiveloo M, Puvananayagam T, Albu JB, Lu-Yao GL. Lifestyle, anthropometric, and obesity-related physiologic determinants of insulin-like growth factor-1 in the Third National Health and Nutrition Examination Survey (1988-1994). *Ann Epidemiol* 2010;20:182-193.
21. Crowe FL, Key TJ, Allen NE, et al. A cross-sectional analysis of the associations between adult height, BMI and serum concentrations of IGF-I and IGFBP-1 -2 and -3 in the European Prospective Investigation into Cancer and Nutrition (EPIC). *Ann Hum Biol* 2010;38:194-202.
22. Lukanova A, Soderberg S, Stattin P, et al. Nonlinear relationship of insulin-like growth factor (IGF)-I and IGF-I/IGF-binding protein-3 ratio with indices of adiposity and plasma insulin concentrations (Sweden). *Cancer Causes Control* 2002;13:509-516.
23. Sandhu MS, Gibson JM, Heald AH, Dunger DB, Wareham NJ. Low circulating IGF-II concentrations predict weight gain and obesity in humans. *Diabetes* 2003;52:1403-1408.
24. Kuh D, Pierce M, Adams J, et al. Updating the cohort profile for the MRC National Survey of Health and Development: a new clinic-based data collection for ageing research. *Int J Epidemiol* 2011;40:e1-e9.
25. Benn RT. Some mathematical properties of weight-for-height indices used as measures of adiposity. *Br J Prev Soc Med* 1971;25:42-50.
26. Jakobsdottir S, van Nieuwpoort IC, Schaap LA, van Schoor NM, Lips P, Drent ML. Serum insulin-like growth factor-I and body composition in community dwelling older people. *Clin Endocrinol (Oxf)* 2010;73:173-180.
27. Chaston TB, Dixon JB, O'Brien PE. Changes in fat-free mass during significant weight loss: a systematic review. *Int J Obes* 2006;31:743-750.
28. Cooper R, Mishra G, Clennell S, Guralnik J, Kuh D. Menopausal status and physical performance in midlife: findings from a British birth cohort study. *Menopause* 2008;15:1079-1085.
29. Soubry A, Il'yasova D, Sedjo R, et al. Increase in circulating levels of IGF-1 and IGF-1/IGFBP-3 molar ratio over a decade is associated with colorectal adenomatous polyps. *Int J Cancer* 2012;131:512-517.
30. Martin RM, Holly JM, Davey SG, Gunnell D. Associations of adiposity from childhood into adulthood with insulin resistance and the insulin-like growth factor system: 65-year follow-up of the Boyd Orr Cohort. *J Clin Endocrinol Metab* 2006;91:3287-3295.
31. Andersen M, Brixen K, Hagen C, Frystyk J, Nielsen TL. Positive associations between serum levels of IGF-I and subcutaneous fat depots in young men. The Odense Androgen Study. *Growth Hormone IGF Res* 2012;22:139-145.
32. Nindl BC, Santtila M, Vaara J, Hakkinen K, Kyrolainen H. Circulating IGF-I is associated with fitness and health outcomes in a population of 846 young healthy men. *Growth Horm IGF Res* 2011;21:124-128.

33. Harris TB, Kiel D, Roubenoff R, et al. Association of insulin-like growth factor-I with body composition, weight history, and past health behaviors in the very old: the Framingham Heart Study. *J Am Geriatr Soc* 1997;45:133-139.

34. Crowe FL, Key TJ, Allen NE, et al. The association between diet and serum concentrations of IGF-I, IGFBP-1, IGFBP-2, and IGFBP-3 in the European Prospective Investigation into Cancer and Nutrition. *Cancer Epidemiol Biomarkers Prev* 2009;18:1333-1340.

35. Nindl BC, Urso ML, Pierce JR, et al. IGF-I measurement across blood, interstitial fluid, and muscle biocompartments following explosive, high-power exercise. *Am J Physiol Regulat Integr Comp Physiol* 2012;303:R1080-R1089.

36. Firth SM, Baxter RC. Cellular actions of the insulin-like growth factor binding proteins. *Endocr Rev* 2002;23:824-854.

37. Nindl BC, Pierce JR. Insulin-like growth factor I as a biomarker of health, fitness, and training status. *Med Sci Sports Exerc* 2010;42:39-49.

38. Ben-Shlomo Y, Holly J, McCarthy A, Savage P, Davies D, Davey Smith G. Prenatal and postnatal milk supplementation and adult insulin-like growth factor I: long-term follow-up of a randomized controlled trial. *Cancer Epidemiol Biomarkers and Prevent* 2005;14:1336-1339.

39. Holt RI, Erotokritou-Mulligan I, Ridley SA, et al. A determination of the pre-analytical storage conditions for insulin like growth factor-I and type III procollagen peptide. *Growth Horm IGF Res* 2009;19:43-50.

40. Burgers AM, Biermasz NR, Schoones JW, et al. Meta-analysis and dose-response metaregression: circulating insulin-like growth factor I (IGF-I) and mortality. *J Clin Endocrinol Metab* 2011;96:2912-2920.